RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $6 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $6 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | -0% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 91.4% | 93.6% | 99.9% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -1,826.2% | 73% | -1,680% | -1,627.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,249.8% | -2,081.8% | -1,984.1% | -1,829% |
| EPS Diluted | -1 | -0.014 | -0.013 | -0.012 |
| % Growth | -7,094.2% | -6.1% | -10.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |